Behavioural studies on the potential of NMDA receptor antagonists as analgesics

Boyce, Susan; Rupniak, N. M. J.

doi:10.1007/978-3-0348-8139-5_8

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

2018

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A shift in the receptor population towards a more favourable conformation for ACBC would support the premise that ACBC and 7‐CK act in vivo at NMDA receptor sites to produce antinociception. However, compounds that inhibit NMDA receptor activation produce ataxia in animal models (Boyce & Rupniak, ). In our studies, the highest dose of ACBC administered systemically or intrathecally did not produce ataxia in most animals or was transient in three of 20 animals.…”

Section: Discussionmentioning

confidence: 99%

Antinociception by intrathecal delivery of the novel non‐opioid 1‐amino‐1‐cyclobutanecarboxylic acid

Fung

Asiri

Taheri³

et al. 2018

European Journal of Pain

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Antinociception by intrathecal delivery of the novel non‐opioid 1‐amino‐1‐cyclobutanecarboxylic acid

Fung

Asiri

Taheri³

et al. 2018

European Journal of Pain

View full text Add to dashboard Cite

show abstract

New Treatments for Neuropathic Pain

Rice

Hill²

2006

Annu. Rev. Med.

View full text Add to dashboard Cite

Existing treatments for neuropathic pain deliver inadequate pain relief, unacceptable side effects, or both. The unmet medical need for more effective treatment is driving a large volume of research to discover new drugs. Most existing treatments are drugs introduced to treat other pain conditions or other medical conditions, such as antidepressants and anticonvulsants, which were found empirically to be effective for neuropathic pain. Only recently have drug discovery efforts have become mechanistically driven, addressing targets identified by a molecular neurobiological approach to the pathophysiology of neuropathic states.

show abstract

Behavioural studies on the potential of NMDA receptor antagonists as analgesics

Cited by 2 publications

References 67 publications

Antinociception by intrathecal delivery of the novel non‐opioid 1‐amino‐1‐cyclobutanecarboxylic acid

Antinociception by intrathecal delivery of the novel non‐opioid 1‐amino‐1‐cyclobutanecarboxylic acid

New Treatments for Neuropathic Pain

Contact Info

Product

Resources

About